{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:14:13Z","timestamp":1793070853951,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clgc.2023.02.007","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T05:38:32Z","timestamp":1676525912000},"page":"357-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7877-9585","authenticated-orcid":false,"given":"Hartlee","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3526-3938","authenticated-orcid":false,"given":"Allison M.","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine P.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6536-0902","authenticated-orcid":false,"given":"Bianka","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-2487","authenticated-orcid":false,"given":"Tracy L.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clgc.2023.02.007_bib0001","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s12032-018-1217-1","article-title":"Contemporary treatment of metastatic renal cell carcinoma","volume":"35","author":"Wiechno","year":"2018","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2023.02.007_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0391560318802166","article-title":"Systemic therapy of metastatic renal cell carcinoma: review of the current literature","volume":"86","author":"Zerdes","year":"2019","journal-title":"Urologia"},{"issue":"4","key":"10.1016\/j.clgc.2023.02.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120877","article-title":"A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting","volume":"10","author":"Fishman","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.clgc.2023.02.007_bib0004","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.eururo.2015.07.006","article-title":"Long-term safety of sunitinib in metastatic renal cell carcinoma","volume":"69","author":"Porta","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2023.02.007_bib0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9807","key":"10.1016\/j.clgc.2023.02.007_bib0006","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.clgc.2023.02.007_bib0007","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2023.02.007_bib0008","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2023.02.007_bib0009","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"14","key":"10.1016\/j.clgc.2023.02.007_bib0010","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.02.007_bib0011","doi-asserted-by":"crossref","first-page":"ixe13","DOI":"10.1016\/S0923-7534(20)34325-8","article-title":"Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): results of the comparz trial","volume":"23","author":"Motzer","year":"2012","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.clgc.2023.02.007_bib0012","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clgc.2023.02.007_bib0013","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/jjco\/hyy078","article-title":"Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma","volume":"48","author":"Ishihara","year":"2018","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2023.02.007_bib0014","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"issue":"8","key":"10.1016\/j.clgc.2023.02.007_bib0015","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus Sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2023.02.007_bib0016","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/1078155219875509","article-title":"Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials","volume":"26","author":"McElwee","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clgc.2023.02.007_bib0017","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2020.09.030","article-title":"Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL early access program","volume":"142","author":"Albiges","year":"2021","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2023.02.007_bib0018","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2023.02.007_bib0019","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2021.12.024","article-title":"Assessing the safety and efficacy of two starting doses of lenvatinib plus everolimus in patients with renal cell carcinoma: a randomized phase 2 trial","volume":"82","author":"Pal","year":"2022","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:38:07Z","timestamp":1761565087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323000381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1558767323000381"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.02.007","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}